An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Most Cited Paper
in Animal Virus Infections Studies
18 Months Post-Publication
Class of 2026
“An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
GEMCOVAC-OM · self-amplifying mRNA vaccine · Omicron BA.1 · B.1.1.529 · Intradermal administration · thermostable vaccine · BBV152 · ChAdOx1 nCoV-19 · GEMCOVAC-19 · D614G variant · anti-spike IgG antibodies · Neutralizing antibodies · Neutralization assay · seroconversion · Booster vaccination · Phase 2/3 trial · Monovalent vaccine · variant-specific immunogenicity
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Animal Virus Infections Studies Papers, Class of 2026. https://pri.pepkio.com/top-papers/animal-virus-infections-studies/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459